Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

896
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
896
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.5K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.5K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sporadic Creutzfeldt-Jakob disease following venison exposure in a chronic wasting disease-endemic region: a zoonotic surveillance perspective.

Frontiers in public health·2026
Same author

The Ste20 kinase TAOK3 restrains Rac-driven cytoskeletal-mitochondrial coupling to preserve naive CD8<sup>+</sup> T cell homeostasis and activation.

Frontiers in immunology·2026
Same author

Assessing the capability of large language models in answering pediatric critical care board-style questions.

Scientific reports·2026
Same author

<i>Trans</i>-eQTLs reveal the architecture of human gene regulatory networks.

medRxiv : the preprint server for health sciences·2026
Same author

<i>The Safer Spaces Project</i>: a whole of community systems approach to co-designing and implementing a 'Safer Spaces' model of primary healthcare for LGBTQ+ young people in Western Victoria - a protocol for a mixed-methods study.

BMJ open·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026

Related Experiment Video

Updated: Jan 12, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.2K

ALSUntangled #81: Pyridostigmine (mestinon®).

Nadia Mansoor1, Terry Heiman-Patterson1, Eva L Feldman2,3

  • 1Neurology Department, Temple University, Philadelphia, PA, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|November 6, 2025
PubMed
Summary

Pyridostigmine does not slow Amyotrophic Lateral Sclerosis (ALS) progression. This drug, which enhances neuromuscular transmission, lacks a clear mechanism to modify ALS pathophysiology and has shown no efficacy in clinical trials for ALS patients.

Keywords:
Acetylcholinesterase inhibitoramyotrophic lateral sclerosismotor neuron diseaseneuromuscular junctionoff-label use

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

14.0K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.2K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

14.0K

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Neuromuscular junction dysfunction is an early feature of Amyotrophic Lateral Sclerosis (ALS).
  • Pyridostigmine enhances acetylcholine availability, potentially improving neuromuscular transmission in ALS.
  • The role of altered neuromuscular transmission in ALS progression remains uncertain.

Purpose of the Study:

  • To evaluate the potential of pyridostigmine in slowing ALS progression.
  • To assess the mechanistic plausibility of pyridostigmine's efficacy in ALS.
  • To review existing clinical evidence for anticholinesterase agents in ALS.

Main Methods:

  • Review of preclinical findings on neuromuscular junction dysfunction in ALS.
  • Analysis of pyridostigmine's proposed mechanisms of action in ALS.
  • Examination of clinical trial data for pyridostigmine and similar agents in ALS patients.

Main Results:

  • Pyridostigmine lacks plausible mechanisms to modify ALS pathophysiology beyond transient neuromuscular transmission enhancement.
  • Patients with ALS (PALS) positive for acetylcholine receptor autoantibodies without myasthenia gravis symptoms are unlikely to benefit.
  • Clinical trials involving similar anticholinesterase agents did not demonstrate a slowing of ALS progression.

Conclusions:

  • Pyridostigmine is not supported for use in slowing ALS progression due to lack of mechanistic rationale and proven efficacy.
  • Common side effects include muscarinic cholinergic symptoms, particularly gastrointestinal issues.
  • Further clinical investigation into pyridostigmine for ALS is not warranted based on current evidence.